Our content partners

Together with Immunexpress we focus on the development and commercialization of SeptiCyte® RAPID on the Idylla™ Platform.  SeptiCyte® RAPID is a rapid host-response gene expression signature test that distinguishes sepsis from non-infectious systemic inflammation (INSI/SIRS). It provides actionable results in about one hour enabling physicians to optimize their patient management decisions.

Together with GeneproDX we focus on the development and commercialization of ThyroidPrint® for use on the Idylla™ Platform. ThyroidPrint® is a gene expression signature (GEP) test that can identify patients with indeterminate thyroid FNA (fine needle aspiration biopsy) that can safely forego thyroid surgery.

Together with APIS Technology Assays we focus on the development of the APIS Breast Cancer Subtyping Assay on Biocartis’ rapid and easy-to-use molecular diagnostics platform Idylla™.